EMG
CHRS icon

ETF Managers Group’s Coherus Oncology CHRS Stock Holding History

ETF Managers Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,690
Closed -$272K – 722
2022
Q2 		$272K Buy
+36,690
New +$319K 0.01% 615
2022
Q1 		– Sell
-30,650
Closed -$513K – 713
2021
Q4 		$513K Buy
+30,650
New +$536K 0.01% 518

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ETF Managers Group's CHRS Position: Q3 2022 in Review

ETF Managers Group sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 36,690 shares — an estimated $272K sold.

ETF Managers Group first reported a position in CHRS in Q4 2021 and held it in 2 quarters. The position peaked at $513K in Q4 2021. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

  • ETF Managers Group reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
  • ETF Managers Group sold 36,690 Coherus Oncology shares in Q3 2022, an estimated $272K.
  • ETF Managers Group first reported a position in Coherus Oncology in Q4 2021 and held it in 2 quarters.
  • ETF Managers Group's Coherus Oncology position peaked at $513K in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.